Rodriguez-Vida A - Search Results

1

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).

Grivas P, Loriot Y, Morales-Barrera R, Teo MY, Zakharia Y, Feyerabend S, Vogelzang NJ, Grande E, Adra N, Alva A, Necchi A, Rodriguez-Vida A, Gupta S, Josephs DH, Srinivas S, Wride K, Thomas D, Simmons A, Loehr A, Dusek RL, Nepert D, Chowdhury S. Grivas P, et al. BMC Cancer. 2021 May 24;21(1):593. doi: 10.1186/s12885-021-08085-z. BMC Cancer. 2021. PMID: 34030643 Free PMC article. Clinical Trial.

2

Causes of death in men with prostate cancer: an analysis of 50,000 men from the Thames Cancer Registry.

Chowdhury S, Robinson D, Cahill D, Rodriguez-Vida A, Holmberg L, Møller H. Chowdhury S, et al. BJU Int. 2013 Jul;112(2):182-9. doi: 10.1111/bju.12212. BJU Int. 2013. PMID: 23795786

3

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.

Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, de Bono JS. Bianchini D, et al. Eur J Cancer. 2014 Jan;50(1):78-84. doi: 10.1016/j.ejca.2013.08.020. Epub 2013 Sep 25. Eur J Cancer. 2014. PMID: 24074764

4

The role of metastasectomy in renal cell carcinoma.

Josephides E, Rodriguez-Vida A, Galazi M, Chowdhury S, Suder A. Josephides E, et al. Expert Rev Anticancer Ther. 2013 Dec;13(12):1363-71. doi: 10.1586/14737140.2013.856762. Expert Rev Anticancer Ther. 2013. PMID: 24236818 Review.

5

Cytoreductive nephrectomy: past, present and future.

Galazi M, Rodriguez-Vida A, Josephides E, Chau NM, Chowdhury S. Galazi M, et al. Expert Rev Anticancer Ther. 2014 Mar;14(3):271-7. doi: 10.1586/14737140.2014.864240. Epub 2014 Jan 6. Expert Rev Anticancer Ther. 2014. PMID: 24392671 Review.

6

Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer.

Lorente D, Bianchini D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, De Bono JS. Lorente D, et al. Eur J Cancer. 2014 Mar;50(5):1042-3. doi: 10.1016/j.ejca.2013.12.016. Epub 2014 Jan 13. Eur J Cancer. 2014. PMID: 24433842 No abstract available.

7

Mammalian target of rapamycin (mTOR)-related non-infectious pneumonitis: a potential biomarker of clinical benefit?

Rodriguez-Vida A, Chau NM, Chowdhury S. Rodriguez-Vida A, et al. BJU Int. 2014 Mar;113(3):350-1. doi: 10.1111/bju.12493. BJU Int. 2014. PMID: 24528875 No abstract available.

8

Is there an antiandrogen withdrawal syndrome with enzalutamide?

Rodriguez-Vida A, Bianchini D, Van Hemelrijck M, Hughes S, Malik Z, Powles T, Bahl A, Rudman S, Payne H, de Bono J, Chowdhury S. Rodriguez-Vida A, et al. BJU Int. 2015 Mar;115(3):373-80. doi: 10.1111/bju.12826. Epub 2014 Oct 24. BJU Int. 2015. PMID: 24906049

9

Precision medicine for prostate cancer.

Galazi M, Rodriguez-Vida A, Ng T, Mason M, Chowdhury S. Galazi M, et al. Expert Rev Anticancer Ther. 2014 Nov;14(11):1305-15. doi: 10.1586/14737140.2014.972948. Epub 2014 Oct 30. Expert Rev Anticancer Ther. 2014. PMID: 25354871 Review.

10

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

Rodriguez-Vida A, Galazi M, Rudman S, Chowdhury S, Sternberg CN. Rodriguez-Vida A, et al. Drug Des Devel Ther. 2015 Jun 29;9:3325-39. doi: 10.2147/DDDT.S69433. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26170619 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

76 results

Search Page